Cumberland Pharmaceuticals (CPIX) Cash & Equivalents (2010 - 2026)

Cumberland Pharmaceuticals has reported Cash & Equivalents for 17 years, with the latest figure at $11.0 million in Q1 2026.

• Quarterly Cash & Equivalents fell 27.14% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (down 27.14% YoY) and the FY2025 annual result came in at $11.4 million, down 36.29% from the prior year.
• Cash & Equivalents eased to $11.0 million in Q1 2026 per CPIX's latest filing, from $11.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $19.8 million in Q4 2022 and troughed at $11.0 million in Q1 2026.
• A 5-year average of $16.8 million and a median of $17.5 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents rose 13.2% in 2024, then plunged 36.29% in 2025.
• Over 5 years, Cash & Equivalents stood at $19.8 million in 2022, then fell by 7.27% to $18.3 million in 2023, then retreated by 1.95% to $18.0 million in 2024, then slumped by 36.29% to $11.4 million in 2025, then fell by 3.82% to $11.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $11.0 million, $11.4 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.